These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24013002)

  • 1. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
    Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
    Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.
    Qi X; Bae A; Liu S; Yang H; Sun SC; Harris J; Delaney W; Miller M; Mo H
    Antiviral Res; 2009 Feb; 81(2):166-73. PubMed ID: 19063924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
    Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
    Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
    Vijgen L; Verbeeck J; Van Kerckhove B; Berke JM; Koletzki D; Fanning G; Lenz O
    Methods Mol Biol; 2013; 1030():105-17. PubMed ID: 23821263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.
    Tripathi RL; Krishnan P; He Y; Middleton T; Pilot-Matias T; Chen CM; Lau DT; Lemon SM; Mo H; Kati W; Molla A
    Antiviral Res; 2007 Jan; 73(1):40-9. PubMed ID: 16914212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
    Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays.
    Verbinnen T; Jacobs T; Vijgen L; Ceulemans H; Neyts J; Fanning G; Lenz O
    J Antimicrob Chemother; 2012 Oct; 67(10):2327-37. PubMed ID: 22723600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper.
    Welker MW; Susser S; Welsch C; Perner D; Füller C; Kronenberger B; Herrmann E; Zeuzem S; Sarrazin C
    J Viral Hepat; 2012 Nov; 19(11):775-83. PubMed ID: 23043384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
    Xu J; Liu S; Xu Y; Tien P; Gao G
    Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally.
    Graci JD; Jung SP; Pichardo J; Lahser F; Tong X; Gu Z; Colacino JM
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7060-7066. PubMed ID: 27620477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.
    Sun SC; Bae A; Qi X; Harris J; Wong KA; Miller MD; Mo H
    J Viral Hepat; 2011 Dec; 18(12):861-70. PubMed ID: 21108698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic variation in the hepatitis C virus NS4B protein dramatically influences RNA replication.
    Blight KJ
    J Virol; 2007 Jun; 81(11):5724-36. PubMed ID: 17360748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.
    Yang H; Yang C; Wang Y; Rhodes G; Robinson M; Cheng G; Qi X; Mo H; Tian Y; Pakdaman R; Sheng XC; Kim CU; Delaney WE
    Antivir Ther; 2017; 22(5):413-420. PubMed ID: 28106531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.